Targeting melanomas with our own immune systems sounds like a great idea, but so far reality hasn't matched expectations, with a number of high-profile vaccines recently failing to deliver in clinical trials. But pharmaceutical companies are still trying, because the payoff would be huge for a general melanoma vaccine that works across subtypes, avoiding the need for costly genetic tests. One of the latest contenders is POL-103A, an immune system booster that contains proteins shed from three melanoma cell lines. Developed by Polynoma/CK Life Sciences, this vaccine may help people particularly at risk of melanoma recurrence. If clinical trials continue to uphold its promise, it could launch in 2017.